Latent Class Trajectory Modeling of 2‐Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease‐Modifying Antirheumatic Drugs
Open Access
- 31 May 2020
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (10) , 1632-1642
Abstract
Objective: To determine whether using a reweighted disease activity score that better reflects joint synovitis, i.e., the 2‐component Disease Activity Score in 28 joints (DAS28) (based on swollen joint count and C‐reactive protein level), produces more clinically relevant treatment outcome trajectories compared to the standard 4‐component DAS28.Methods: Latent class mixed modeling of response to biologic treatment was applied to 2,991 rheumatoid arthritis (RA) patients in whom treatment with a biologic disease‐modifying antirheumatic drug was being initiated within the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort, using both 4‐component and 2‐component DAS28 scores as outcome measures. Patient groups with similar trajectories were compared in terms of pretreatment baseline characteristics (including disability and comorbidities) and follow‐up characteristics (including antidrug antibody events, adherence to treatments, and blood drug levels). We compared the trajectories obtained using the 4‐ and 2‐component scores to determine which characteristics were better captured by each.Results: Using the 4‐component DAS28, we identified 3 trajectory groups, which is consistent with previous findings. We showed that the 4‐component DAS28 captures information relating to depression. Using the 2‐component DAS28, 7 trajectory groups were identified; among them, distinct groups of nonresponders had a higher incidence of respiratory comorbidities and a higher proportion of antidrug antibody events. We also identified a group of patients for whom the 2‐component DAS28 scores remained relatively low; this group included a high percentage of patients who were nonadherent to treatment. This highlights the utility of both the 4‐ and 2‐component DAS28 for monitoring different components of disease activity.Conclusion: Here we show that the 2‐component modified DAS28 defines important biologic and clinical phenotypes associated with treatment outcome in RA and characterizes important underlying response mechanisms to biologic drugs.Keywords
Funding Information
- Medical Research Council (MR/K015346/1, MR/N00583X/1)
- Versus Arthritis (21754, 22072)
This publication has 34 references indexed in Scilit:
- Temporal representation of care trajectories of cancer patients using data from a regional information system: an application in breast cancerBMC Medical Informatics and Decision Making, 2014
- Patterns of Obesity Development before the Diagnosis of Type 2 Diabetes: The Whitehall II Cohort StudyPLOS Medicine, 2014
- Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid ArthritisArthritis Care & Research, 2013
- Distinct Trajectories of Disease Activity Over the First Year in Early Rheumatoid Arthritis Patients Following a Treat‐to‐Target StrategyArthritis Care & Research, 2013
- Trajectories of functional limitation in early rheumatoid arthritis and their association with mortalityRheumatology, 2013
- Comparative analysis of missing value imputation methods to improve clustering and interpretation of microarray experimentsBMC Genomics, 2010
- Latent Class Models for Joint Analysis of Longitudinal Biomarker and Event Process DataJournal of the American Statistical Association, 2002
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980